Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression

Cancer Immunology, Immunotherapy

Volumn 52, Issue 4, 2003, Pages 235-242

  Masztalerz, Agnieszka ^a   Van Rooijen, Nico ^b   Den Otter, Willem ^a   Everse, Linda A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cancer; Immunotherapy; Interleukin 12; Interleukin 2; Macrophage

Indexed keywords

FC GAMMA RECEPTOR II; FC GAMMA RECEPTOR III; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEPLETION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; FEMALE; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOLOGY; LYMPHOMA; MACROPHAGE FUNCTION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR REGRESSION; TUMOR REJECTION;

EID: 0038408925     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0381-z     Document Type: Article

References (27)

1. Banchereau J, Briere F, Liu YJ, Rousset F (1994) Molecular control of B lymphocyte growth and differentiation. Stem Cells 12:278
2. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254
3. Claassen I, Van Rooijen N, Claassen E (1990) A new method for removal of mononuclear phagocytes from heterogenous cell populations 'in vitro', using the liposome-mediated macrophage 'suicide' technique. J Immunol Methods 134:153
4. De Weger RA, Wilbrink B, Moberts RM, Mans D, Oskam R, Den Otter W (1987) Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice. Cancer Immunol Immunother 24:25
5. Dijstelbloem HM, van de Winkel JG, Kallenberg CG (2001) Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22:510
6. Espinoza-Delgado I, Bosco MC, Musso T, Gusella GL, Longo DL, Varesio L (1995) Interleukin-2 and human monocyte activation. J Leukoc Biol 57:13
7. Espinoza-Delgado I, Longo DL, Gusella GL, Varesio L (1990) IL-2 enhances c-fms expression in human monocytes. J Immunol 145:1137
8. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA (1999) The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 162:4472
9. Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, Fioretti MC, Puccetti P (2001) Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol 167:221
10. Ha SJ, Lee SB, Kim CM, Shin HS, Sung YC (1998) Rapid recruitment of macrophages in interleukin-12-mediated tumour regression. Immunology 95:156
11. Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M (2002) Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 35:329
12. Jackson PG, Evans SR (2000) Intraperitoneal macrophages and tumor immunity: a review. J Surg Oncol 75:146
13. Kovacs EJ, Brock B, Varesio L, Young HA (1989) IL-2 induction of IL-1 beta mRNA expression in monocytes. Regulation by agents that block second messenger pathways. J Immunol 143:3532
14. Maas RA, Dullens HF, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49:7037
15. Metzger DW, Buchanan JM, Collins JT, Lester TL, Murray KS, Van Cleave VH (1996) Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci 795:100
16. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA (1997) Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Eur J Immunol 27:1958
17. Morris SC, Madden KB, Adamovicz JJ, Gause WC, Hubbard BR, Gately MK (1994) Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 152:1047
18. Munder M, Mallo M, Eichmann K, Modolell M (1998) Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 187:2103
19. Philip R (1988) Cytolysis of tumor necrosis factor (TNF)-resistant tumor targets. Differential cytotoxicity of monocytes activated by the interferons, IL-2, and TNF. J Immunol 140:1345
20. Ravetch, JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275
21. Ryffel B (1997) Interleukin-12: role of interferon-gamma in 1L-12 adverse effects. Clin Immunol Immunopathol 83:18
22. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174:83
23. Wahl SM, McCartney-Francis N, Hunt DA, Smith PD, Wahl LM, Katona IM (1987) Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity. J Immunol 139:1342
24. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH (2001) IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108:51
25. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38
26. Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination. Ann N Y Acad Sci 795:434
27. Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW (1996) Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res 56:1131